Cargando…
Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report
BACKGROUND: Giant cell tumour (GCT) of the bone is a rare, invasive benign bone tumour, which typically originates in the metaphyseal ends of long bones and rarely in the spine. Here, we report a rare case of recurrent GCT of the thoracic vertebra, which was managed by three-level total en bloc spon...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023717/ https://www.ncbi.nlm.nih.gov/pubmed/32061254 http://dx.doi.org/10.1186/s12891-020-3129-4 |
_version_ | 1783498311209058304 |
---|---|
author | Duan, Ping-Guo Sheng, Yong-Hong Deng, Chang-Hao Tang, Ben-Yu Yao, Hao-Qun |
author_facet | Duan, Ping-Guo Sheng, Yong-Hong Deng, Chang-Hao Tang, Ben-Yu Yao, Hao-Qun |
author_sort | Duan, Ping-Guo |
collection | PubMed |
description | BACKGROUND: Giant cell tumour (GCT) of the bone is a rare, invasive benign bone tumour, which typically originates in the metaphyseal ends of long bones and rarely in the spine. Here, we report a rare case of recurrent GCT of the thoracic vertebra, which was managed by three-level total en bloc spondylectomy (TES) after denosumab therapy. CASE PRESENTATION: A 50-year-old woman presented with a 2-month history of progressive lower back pain. Magnetic resonance imaging revealed destruction of the T11 vertebra and a soft tissue mass. The patient underwent tumour resection. Computed tomography at the 2-year follow-up revealed relapse of the resected tumour, which had spread to the T12 vertebral body. Subsequently, denosumab therapy was administered to the patient for 1 year. The growth of the tumour was controlled, and its boundary line was clear. Thereafter, TES for the T10-T12 vertebrae was performed, and spinal reconstruction was completed through a one-stage single posterior approach. The patient’s condition improved postoperatively, and no evidence of recurrence of GCT of the bone or spinal deformity was observed at the 32-month follow-up. CONCLUSIONS: Denosumab therapy contributed to tumour regression. Three-level TES may be an effective and feasible strategy for managing large recurrent GCTs of the spine after denosumab therapy. |
format | Online Article Text |
id | pubmed-7023717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70237172020-02-20 Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report Duan, Ping-Guo Sheng, Yong-Hong Deng, Chang-Hao Tang, Ben-Yu Yao, Hao-Qun BMC Musculoskelet Disord Case Report BACKGROUND: Giant cell tumour (GCT) of the bone is a rare, invasive benign bone tumour, which typically originates in the metaphyseal ends of long bones and rarely in the spine. Here, we report a rare case of recurrent GCT of the thoracic vertebra, which was managed by three-level total en bloc spondylectomy (TES) after denosumab therapy. CASE PRESENTATION: A 50-year-old woman presented with a 2-month history of progressive lower back pain. Magnetic resonance imaging revealed destruction of the T11 vertebra and a soft tissue mass. The patient underwent tumour resection. Computed tomography at the 2-year follow-up revealed relapse of the resected tumour, which had spread to the T12 vertebral body. Subsequently, denosumab therapy was administered to the patient for 1 year. The growth of the tumour was controlled, and its boundary line was clear. Thereafter, TES for the T10-T12 vertebrae was performed, and spinal reconstruction was completed through a one-stage single posterior approach. The patient’s condition improved postoperatively, and no evidence of recurrence of GCT of the bone or spinal deformity was observed at the 32-month follow-up. CONCLUSIONS: Denosumab therapy contributed to tumour regression. Three-level TES may be an effective and feasible strategy for managing large recurrent GCTs of the spine after denosumab therapy. BioMed Central 2020-02-15 /pmc/articles/PMC7023717/ /pubmed/32061254 http://dx.doi.org/10.1186/s12891-020-3129-4 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Duan, Ping-Guo Sheng, Yong-Hong Deng, Chang-Hao Tang, Ben-Yu Yao, Hao-Qun Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report |
title | Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report |
title_full | Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report |
title_fullStr | Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report |
title_full_unstemmed | Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report |
title_short | Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report |
title_sort | recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023717/ https://www.ncbi.nlm.nih.gov/pubmed/32061254 http://dx.doi.org/10.1186/s12891-020-3129-4 |
work_keys_str_mv | AT duanpingguo recurrentgiantcelltumourofthethoracicspinemanagedbytotalenblocspondylectomyanddenosumabtherapyacasereport AT shengyonghong recurrentgiantcelltumourofthethoracicspinemanagedbytotalenblocspondylectomyanddenosumabtherapyacasereport AT dengchanghao recurrentgiantcelltumourofthethoracicspinemanagedbytotalenblocspondylectomyanddenosumabtherapyacasereport AT tangbenyu recurrentgiantcelltumourofthethoracicspinemanagedbytotalenblocspondylectomyanddenosumabtherapyacasereport AT yaohaoqun recurrentgiantcelltumourofthethoracicspinemanagedbytotalenblocspondylectomyanddenosumabtherapyacasereport |